Studies using australia's pharmaceutical benefits scheme data for pharmacoepidemiological research: A systematic review of the published literature (1987-2013)

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 5, 2015, Pages 447-455

  Pearson, Sallie Anne ^a,b   Pesa, Nicole ^a   Langton, Julia M ^a   Drew, Annabelle ^c   Faedo, Margaret ^a   Robertson, Jane ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NSW Therapeutic Advisory Group   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Drug utilization; Observational studies; Pharmacoepidemiology; Prescription databases; Record linkage

Indexed keywords

AGENTS ACTING ON THE PERIPHERAL NERVOUS AND NEUROMUSCULAR SYSTEMS; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT; DERMATOLOGICAL AGENT; GASTROINTESTINAL AGENT; IMMUNOMODULATING AGENT; PRESCRIPTION DRUG; RESPIRATORY TRACT AGENT; SEX HORMONE; URINARY TRACT AGENT;

AUSTRALIA; DATA BASE; DRUG COST; DRUG FORMULARY; DRUG USE; DRUG UTILIZATION; EMBASE; HUMAN; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PHARMACEUTICAL BENEFITS SCHEME; PHARMACOEPIDEMIOLOGY; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCREENING; SYSTEMATIC REVIEW; ECONOMICS; POSTMARKETING SURVEILLANCE; PROCEDURES;

AUSTRALIA; DRUG UTILIZATION REVIEW; PHARMACOEPIDEMIOLOGY; PRESCRIPTION DRUGS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84928208911     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3756     Document Type: Review

References (46)

1. Avorn J. In defense of pharmacoepidemiology-embracing the yin and yang of drug research. N Engl J Med 2007; 357: 2219-2221. doi:10.1056/NEJMp0706892.
2. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337. doi:10.1016/j.jclinepi.2004.10.012.
3. Forrow S, Campion DM, Herrinton LJ, Nair VP, Robb MA, Wilson M, Platt R. The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 12-17. doi:10.1002/pds.2242.
4. Platt R, Carnahan RM, Brown JS, Chrischilles E, Curtis LH, Hennessy S, Nelson JC, Racoosin JA, Robb M, Schneeweiss S, et al. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 1-8. doi:10.1002/pds.2343.
5. Psaty BM, Breckenridge AM. Mini-Sentinel and regulatory science-big data rendered fit and functional. N Engl J Med 2014; 370: 2165-2167. doi:10.1056/NEJMp1401664.
6. Wettermark B, Zoega H, Furu K, Korhonen M, Hallas J, Norgaard M, Almarsdottir A, Andersen M, Andersson Sundell K, Bergman U, et al. The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review. Pharmacoepidemiol Drug Saf 2013; 22: 691-699. doi:10.1002/pds.3457.
7. Pharmaceutical Benefits Scheme: expenditure and prescriptions twelve months to 30 June 2003. Canberra, 2003. Available at: http://www.pbs.gov.au/statistics/2002-2003-files/expenditure-and-prescriptions-2002-03.pdf [1 July 2014].
8. Pharmaceutical Benefits Scheme: expenditure and prescriptions twelve months to 30 June 2013. Canberra; 2013. Available at: http://www.pbs.gov.au/info/statistics/expenditure-and-prescriptions-30-06-2013 [1 July 2014].
9. Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health affairs (Project Hope) 2001; 20: 104-114.
10. Lopert R, Elshaug AG. Australia's 'fourth hurdle' drug review comparing costs and benefits holds lessons for the United States. Health affairs (Project Hope) 2013; 32: 778-787. DOI: 10.1377/hlthaff.2012.1058.
11. Pharmaceutical Benefits Scheme: Drug Utilisation Sub Committee (DUSC). Canberra, 2014. Available at: http://www.pbs.gov.au/info/industry/listing/participants/drug-utilisation-subcommittee [1 July 2014].
12. Edmonds DJ, Dumbrell DM, Primrose JG, McManus P, Birkett DJ, Demirian V. Development of an Australian drug utilisation database: a report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee. Pharmacoeconomics 1993; 3: 427-432.
13. The Pharmaceutical Benefits Scheme: Australian Statistics on Medicines 2011. Canberra; 2011. Available at: http://www.pbs.gov.au/info/statistics/asm/asm-2011 [1 July 2014].
14. DVA Factsheet IS160. Concession and benefits: overview of cards available to veterans and their dependents. Canberra; 2014. Available at: http://factsheets.dva.gov.au/factsheets/documents/IS160%20Overview%20of%20Cards%20Available%20to%20Veterans%20and%20Their%20Dependents.pdf [1 July 2014].
15. The Pharmaceutical Benefits Scheme: 4. Patient charges. Canberra; 2014. Available at: http://www.pbs.gov.au/info/healthpro/explanatory-notes/section1/Section_1_4_Explanatory_Notes [1 July 2014].
16. The Department of Health: Pharmaceutical Benefits Scheme collection of under co-payment data. Canberra; 2014. Available at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-under-copayment-data [1 July 2014].
17. Structure and principles. Oslo; 2011. Available at: http://www.whocc.no/atc/structure_and_principles/ [15 June 2014].
18. Hollingworth SA, Nissen LM, Stathis SS, Siskind DJ, Varghese JMN, Scott JG. Australian national trends in stimulant dispensing: 2002-2009. Aust N Z J Psychiatry 2011; 45: 332-336. doi:10.3109/00048674.2010.543413.
19. Leggat PA. Trends in antimalarial prescriptions in Australia 2002 to 2005. J Travel Med 2008; 15: 302-306. doi:10.1111/j.1708-8305.2008.00227.x.
20. McManus P, Henry DA, Birkett DJ. Recent changes in the profile of prescription NSAID use in Australia. Med J Aust 2000; 172: 188.
21. Stephenson CP, Karanges E, McGregor IS. Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Aust N Z J Psychiatry 2013; 47: 74-87. doi:10.1177/0004867412466595.
22. Vitry AI, Thai LP, Lu CY. Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia. Intern Med J 2011; 41: 162-166. doi:10.1111/j.1445-5994.2010.02304.x.
23. Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Ryan P, Shakib S, Esterman A, McDermott RA, Roughead EE. Does antidepressant medication use affect persistence with diabetes medicines? Pharmacoepidemiol Drug Saf 2013; 22: 615-622. doi:10.1002/pds.3424.
24. Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL. Stroke risk and NSAIDs: an Australian population-based study. Med J Aust 2011; 195: 525-529. doi:10.5694/mja11.10055.
25. Pratt N, Andersen M, Bergman U, Choi NK, Gerhard T, Huang C, Kimura M, Kimura T, Kubota K, Lai EC, et al. Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf 2013; 22: 915-924. doi:10.1002/pds.3440.
26. Pratt N, Roughead EE, Ramsay E, Salter A, Ryan P. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a self-controlled case-series analysis in an Australian health care claims database. Drug Safety 2011; 34: 567-575. doi:10.2165/11588470-000000000-00000.
27. Roughead EE, Kalisch LM, Pratt NL, Killer G, Barnard A, Gilbert AL. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol 2012; 19: 74-82. doi:10.3109/09286586.2011.638743.
28. Australian Government Department of Veterans' Affairs. Treatment population statistics: quarterly report June 2014. Canberra; 2014. Available at: http://www.dva.gov.au/aboutDVA/Statistics/Documents/TPopJun2014.pdf [1 August 2014].
29. Population Health Research Network. Perth; 2014. Available at: http://www.phrn.org.au/ [20 July 2014].
30. Begg SVT, Barker B, Stevenson C, Stanley L, Lopez AD. The burden of disease and injury in Australia 2003. Cat. no. PHE 82. Canberra: AIHW; 2007. Available at: http://www.aihw.gov.au/publication-detail/?id=6442467990 [1 August 2014].
31. Damianovich D, Adena M, Tebbutt NC. Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. Br J Cancer 2007; 96: 546-550. doi:10.1038/sj.bjc.6603590.
32. Pearson SA, Ringland CL, Ward RL. Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. J Clin Oncol 2007; 25: 3688-3693.
33. Stavrou EP, Lu CY, Buckley N, Pearson S. The role of comorbidities on the uptake of systemic treatment and 3-year survival in older cancer patients. Ann Oncol 2012; 23: 2422-2428. doi:10.1093/annonc/mdr618.
34. Mealing NM, Dobbins TA, Pearson SA. Validation and application of a death proxy in adult cancer patients. Pharmacoepidemiol Drug Saf 2012; 21: 742-748. doi:10.1002/pds.2257.
35. Cohen SA, Lawson JA, Graudins LV, Pearson S-A, Gazarian M. Changes in anticonvulsant prescribing for Australian children: implications for quality use of medicines. J Paediatr Child Health 2012; 48: 490-495. doi:10.1111/j.1440-1754.2011.02223.x.
36. Hollingworth S, Duhig M, Hall W, Scott J. National trends in the community prescribing of second-generation antipsychotic medications in Australian children and youth: the incomplete story. Australas Psychiatry 2013; 21: 442-445. doi:10.1177/1039856213497809.
37. Kemp A. Hypoallergenic formula prescribing practices in Australia. J Paediatr Child Health 2006; 42: 191-195.
38. Wilson EJ, Nasrin D, Dear KBG, Douglas RM. Changing GPs' antibiotic prescribing: a randomised controlled trial. Commun Dis Intell 2003; 27(Suppl): 32-38.
39. Colvin L, Gill AW, Slack-Smith L, Stanley FJ, Bower C. Off-label use of ondansetron in pregnancy in Western Australia. BioMed Research International 2013; 2013: 909860. DOI: 10.1155/2013/909860.
40. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Pharmacovigilance in pregnancy using population-based linked datasets. Pharmacoepidemiol Drug Saf 2009; 18: 211-225. doi:10.1002/pds.1705.
41. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens. Pharmacoepidemiol Drug Saf 2010; 19: 1137-1150. doi:10.1002/pds.1995.
42. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. [Erratum appears in Birth Defects Res A Clin Mol Teratol. 2011 Apr;91(4):268]. Birth Defects Res A Clin Mol Teratol 2011; 91: 142-152. doi:10.1002/bdra.20773.
43. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia. CNS Drugs 2012; 26: 1-14. doi:10.2165/11634190-000000000-00000.
44. Colvin L, Slack-Smith L, Stanley FJ, Bower C. Are women with major depression in pregnancy identifiable in population health data? BMC Pregnancy Childbirth 2013; 13: 63. DOI: 10.1186/1471-2393-13-63.
45. Vajda FJE, Horgan D, Hollingworth S, Graham J, Hitchcock AA, Roten A, O'Brien TJ, Lander CM, Eadie MJ. The prescribing of antiepileptic drugs for pregnant Australian women. Aust N Z J Obstet Gynaecol 2012; 52: 49-53. DOI: 10.1111/j.1479-828X.2011.01359.x.
46. National Statistical Service. A guide for data integration projects involving commonwealth data for statistical and research projects. Canberra; 2014. Available at: https://statistical-data-integration.govspace.gov.au/roles-and-responsibilities/integrating-authorities/ [1 June 2014].